Article Per Year (5 Year)
p-Index From 2020 - 2025
0.778
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia
Abiyyu Didar Haq
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Antibodi Monoklonal Anti-CD3 Sebagai Terapi Diabetes Mellitus Tipe 1: Sebuah Kajian Sistematis dan Meta-analisis Visakha Vidyadevi Wiguna; Abiyyu Didar Haq; Luh Ade Dita Rahayu
Unram Medical Journal Vol 10 No 3 (2021): Jurnal Kedokteran volume 10 nomor 3 2021
Publisher : Faculty of Medicine Universitas Mataram

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29303/jku.v10i3.580

Abstract

Introduction: Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease which marked by a persistent increase in blood glucose (hyperglycemia). T1DM is thought to be caused by an autoreactivity of T cell which mediates the apoptosis of insulin-producing cells in the pancreas. Those mechanism causes a life-long dependance on exogen insulin. Current immunotherapy strategy is inhibiting or deleting the lymphocyte subset and/or through the use of agents which will induce the tolerance by activating regulatory T cell such as the use of anti-CD3. Therapy using monoclonal antibody also has a continous effect as compared to immunosupressive agents that traditionally being used.Methods: A systematic review was conducted based on PRISMA through PubMed, ScienceDirect, Directory of Open Access Journal, Wiley, Cochrane Library, Google Scholar, and Scopus, searching for randomized controlled trials which analyze anti-CD3’s effects on clinical outcomes of T1DM patients. Studies selected were then assessed for bias risk with CONSORT criteria. Random-effects meta-analysis was performed to estimate the pooled mean difference (MD) along with their 95% confidence intervals (CIs).Results: The search yielded ten RCTs with a total of 1,458 subjects. Anti-CD3 intervention is proven to be effective in reducing insulin’s usage (MD -0,18 [95% CI: -0.22, -0.13],I2=59%, p<0,0001) and HbA1C (MD -0.71[95% CI: -1.18, -0.24], I2=78%, p=0.003) significantly. Furthermore, there is another clinical benefits, such as reducing the decrease of C-peptide response significantly. Conclusion: To conclude, anti CD-3 showed promising results to be widely implemented as treatment for T1DM patients.
POTENSI PITAVASTATIN DENGAN NANOPARTIKEL POLY(DL-LACTIDE-CO-GLYCOLIDE) (PLGA) DRUG DELIVERY SYSTEM SEBAGAI TERAPI ADJUVAN PADA PENYAKIT JANTUNG KORONER Visakha Vidyadevi Wiguna; Abiyyu Didar Haq; Luh Gde Sri Adnyani Suari
JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Vol 9 No 3 (2022): JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia Volume 9.3 Edisi Desember 202
Publisher : BAPIN-ISMKI (Badan Analisis Pengembangan Ilmiah Nasional - Ikatan Senat Mahasiswa Kedokteran Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53366/jimki.v9i3.453

Abstract

ABSTRACT Background: During COVID-19 pandemic, people’s mobility is decreased. This phenomenon leads to the increase of sedentary lifestyle hence increasing the risk of cardiometabolic diseases. One of the disease that has a strong connection with sedentary lifestyle is Coronary Artery Disease (CAD). CAD is the most common cardiovascular disease that causes death contributing as much as 12% of all death in the world. Percutaneous coronary intervention (PCI) therapy in the acute phase of myocardial infarct can lower the infarct area but the risk of ischemic-reperfusion injury limits its therapeutic effect. Methods: This literature review uses journal articles that are sourced from online databases such as PubMed and Google Scholar. The literature search utilized several keywords such as “pitavastatin”, “drug delivery system”, “nanoparticle”, “PLGA”, “myocardial infarction”, “ischemic-reperfusion injury”. The search yielded 34 relevant literatures which used in this literature review Discussion: Pitavastatin is a statin which possesses a significant effect on LDL-C, TG, and HDL-C. Furthermore, pitavastatin also possess cardioprotective effect on ischemic-reperfusion injury by decreasing oxidative stress and increasing intracellular antioxidant. PLGA nanoparticle is proven to increase the therapeutic effect of pitavastatin because of its ability to deliver timely and its anti-inflammatory effect. . Conclusion: Pitavastatin encapsulated by PLGA nanoparticle has the ability to prevent ischemic-reperfusion injury. Current therapeutic strategy has not been able to deliver pitavastatin into the infarct site adequately in the timely manner hence PLGA needed as drug delivery system.
Co-Authors Adli Putra Nugraha Cut Warnaini Febbi Anggy Fiana Damayanti I Komang Gede Andhika Wibisana Luh Ade Dita Rahayu Luh Gde Sri Adnyani Suari Ni Putu Visty Widhiani R.R. Ditya Mutiara Syifa Visakha Vidyadevi Wiguna Visakha Vidyadevi Wiguna Visakha Vidyadevi Wiguna